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Background: It is important to understand the ability to inhibit mycobacterial growth
in healthy adults who would have been Bacillus Calmette-Guérin (BCG) vaccinated in
childhood as this group will be the potential target population for novel booster TB
vaccine trials. In this study we investigated not only the long-term immunity induced by
childhood BCG vaccination but also protective immunity in terms of the ability to inhibit
mycobacterial growth in those who were BCG vaccinated in childhood, with evidence of
recent or remote TB infection.
Methods: We measured the baseline immune response using a functional
mycobacterial growth inhibition assay (MGIA) as a novel approach and an intracellular
cytokine staining (ICS) assay as a reference approach in healthy adults, with different
status of Mycobacterium tuberculosis (Mtb) infection.
Results: Based on MGIA responses in historically BCG-vaccinated healthy adults,
demographical characteristics including age, and gender did not affect mycobacterial
growth inhibition in PBMC. However, the uninfected healthy control (HC) group showed
a greater ability to inhibit mycobacterial growth compared with the latent TB infection
(LTBI) group (P = 0.0005). In terms of theM. tuberculosis antigen-specific T-cell immune
response in diluted whole blood quantitated using an ICS assay, the LTBI group had
a higher frequency of polyfunctional CD 4+ T cells compared with the HC group (P =
0.0002), although there was no correlation between ICS and the MGIA assay.
Conclusion: The Mtb infection status had a significant impact on mycobacterial growth
inhibition in PBMC from healthy adults in South Korea, a country with an intermediate
burden of tuberculosis, with healthy controls showing the greatest mycobacterial
growth inhibition.
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INTRODUCTION
Pulmonary tuberculosis (TB) is an airborne infectious disease
caused by Mycobacterium tuberculosis (Mtb), which is a
significant burden for the world, reaching 9.6 million new TB
cases and 1.5 million deaths per year (1). Also, just under a
quarter of the global population is latently infected withMtb, and
5–10% of them will develop TB in their lifetimes (2). Although
there has been a noteworthy improvement in controlling TB
since the mid-1960s associated with economic growth (3, 4), TB
still remains a major public health problem in South Korea (S.
Korea), a country with an intermediate burden of TB with an
estimated TB prevalence rate of 70.4 per 100,000 population (5).
The age distribution of TB in S. Korea shows incidence peaks in
those aged between 20 and 30 years of age and the elderly (above
65 years of age) (3, 6, 7). This may indicate ongoing transmission
at the community level, as TB cases mainly occurred in the young
adult group (following recent infection) and in the old age group
(resulting from remote infection and reactivation). Considering
the characteristics of TB epidemiology of S. Korea as a mixture,
with high prevalence of TB in the elderly and outbreaks in certain
populations such as close contacts of patients with TB, health care
workers at workplaces, and immigrants from high TB burden
countries etc., there is a need for new TB vaccines to control
tuberculosis in S. Korea. In line with the goal of the national TB
control plan to reach 50% reduction in TB incidence by the year
2020, the introduction of novel TB vaccines to adults together
with continued Bacillus Calmette-Guérin (BCG) vaccination to
infants might be one of the most effective strategies for S. Korea
as well as for other Asian countries in similar situations. However,
BCG is the only vaccine available and has been used for more
than 90 years. Based on numerous studies, BCG vaccine efficacy
varies widely (from 0 to 80%) between geographical locations,
with demographical characteristics, and with the socio-economic
status of the populations (8, 9). With this partial protective
efficacy of BCG in humans, it is important to introduce novel
TB vaccine candidates that will work for all ages, regions, and
regardless of the HIV epidemic, along with improvement of rapid
diagnosis and effective drug treatments. With continuous efforts
to overcome the hurdles for effective TB vaccine development
including the absence of a predictive animal model or validated
correlates of protection, we need to prioritize vaccine candidates
that would be effective across the entire spectrum of TB infection
ranging from latent TB infection (LTBI) to active TB disease.
In order not to embark on a costly vaccine efficacy trial
without a high chance of success, it would be very helpful to
have one or more biomarkers as a “correlation of protection.”
Coordinated by the TuBerculosis Vaccine Initiative (TBVI),
research groups as part of Work Package (WP) #5 in the
EU Horizon 2020 TBVAC2020 consortium have been working
to develop novel biomarker assays with a common goal to
identify, test, evaluate, and prioritize surrogate-endpoints of
protection against human TB, which would give us information
about vaccine induced immunogenicity and the potential
efficacy of novel vaccine candidates at an early stage of the
developmental pipeline (10). Recently, in vitro mycobacterial
growth inhibition assays (MGIA) as functional measures of
human protective responses using the commercial BACTEC
machine has been standardized, with recommendations made
for its use in vaccine and other studies (11–15). A number of
different MGIA assays have been used in animal and human
studies (13, 15–21). For example, the MGIA can be performed
with different cell types (whole blood-based or PBMC-based),
using different mycobacteria (BCG or M. tuberculosis H37Rv),
different protocols (in rotating tubes or in static 48-well
plates) and using different study populations with different
infection status and geography. The precise mechanisms of
mycobacterial growth inhibition remain to be identified, despite
a number of studies (10, 12, 22). Compared to classical
read-outs such as the IFN-γ Enzyme-Linked ImmunoSpot
(ELISpot), or the IFN-γ enzyme-linked immunosorbent assay
(ELISA), and intercellular cytokine staining (ICS) flow cytometry
assays, a MGIA is a more direct way of assessing anti-
mycobacterial immunity. Particularly, the group at the University
of Oxford has contributed significantly to the development
of the optimized MGIA assay through the TBVAC2020
project, and active collaboration with the European Research
Infrastructures for Poverty Related Diseases (EURIPRED)
project on standardizing MGIA, ICS and Luminex assays for
identification and evaluation of potential immune correlates in
humans, non-human primates (NHP) and mice (22–25). The
current MGIA protocol uses reference mycobacteria, exploits the
commercial BACTEC MGIT 960 system (http://www.euripred.
eu/information-trainings/sops-assay-harmonization.html) and
was developed from an earlier protocol used for TB drug
evaluation (26). Alternative approaches to MGIA have used
recombinant BCG such as BCGlux or combinations of antigen-
stimulated lymphocytes and monocytes (13, 27, 28), but these
assays are more complex and many therefore be less suited for
use in vaccine trials. In a joint effort between the research groups
of Workpackage 5 in TBVAC2020, and EU-funded consortium
aiming to facilitate the development of new TB vaccines, a
number of biomarker studies using human MGIA assays have
been on-going. For example, Joosten et al. and O’Shea et al.
observed strongmycobacterial growth inhibition, compared with
other immune assays including ICS and Luminex on the samples
from the same clinical cohorts (17, 24). When the MGIA assay
was used in studies of BCG vaccinated infants, greater growth
inhibition was observed following BCG vaccination than in
unvaccinated controls (29). Tanner et al. also developed an
in vitro model to assess the impact of monocyte phenotype on
the ability to control mycobacterial growth, in order to identify
immune mechanisms (13). Based on these research activities of
a number of research groups using different human cohorts and
sample repositories from different settings, standardized MGIA
assays can now be used for assessment of mycobacterial growth
inhibition in clinical cohorts (23).
Prior to a clinical trial of novel TB vaccine candidates in
South Korea, such as the subunit ID-93 vaccine/GLA-SE vaccine
candidate, being developed for prevention of TB infection (30–
32), this study was carried out to measure baseline immune
responses using MGIA assays (as a novel assay) compared with
ICS assays (as a reference assay) in healthy adults aged more than
20 years old.
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MATERIALS AND METHODS
Study Participants and Sample Collection
Healthy adults aged more than 20 years old were recruited from
the SeveranceHospital, Seoul, S. Korea between January 2016 and
September 2017. Individuals with any acute or chronic disease,
with a previous history of active TB, or with any suggestive
symptoms of TB were excluded. BCG vaccination status was also
assessed based on the survey as well as on-the-spot inspection
of BCG scar on the left or right upper arm. However, >90% of
adults in S. Korea would have been BCG vaccinated in childhood
as per the vaccination policy regardless of the presence of a
BCG scar(s). The status of Mtb infection was assessed using
the QuantiFERON-TB R© Gold In-tube assay (QFT). None of
the participants in this study had HIV infection; a chronic
comorbidity such as diabetes mellitus, chronic renal failure,
malignant tumors, or chronic liver disease; immunosuppressive
status; or acute infections. This study was approved by the
Institutional Review Board of Severance Hospital (IRB No. 4-
2014-1108). All participants provided written informed consent
to use their clinical information and specimens for evaluation
of TB biomarkers. Peripheral blood from all participants was
collected into sodium heparin tubes (Becton, Dickinson (BD),
New Jersey, USA) for QFT, MGIA, and ICS assays.
The Mycobacterium bovis BCG (Pasteur 1173P2) batch used
was prepared and provided by the Aeras Foundation after testing
for “viability and reproducibility” prior to distribution through
the TBVAC2020 partnership (12).
QFT
At baseline all participants were tested using a TB-specific
interferon gamma release assay, the QFT assay (Qiagen,
Hilden, Germany) performed according to the manufacturer’s
instructions. Briefly, 1mL of whole blood was collected in
each of three tubes pre-coated with Mycobacterium tuberculosis-
specific peptides (ESAT-6, CFP-10, and TB7.7) or mitogen
(positive control) and incubated for 16–24 h at 37◦C. For
negative controls, whole blood was placed in tubes that were
not pre-coated. The plasma supernatant was harvested by
centrifugation at 3,000 × g for 15min and stored at −80◦C. The
concentration of IFN-γ was determined using the QFT Enzyme-
linked Immunosorbent Assay (ELISA) Kit. All quantitative QFT
test results were expressed as IFN-γ concentration (IU/mL) and
qualitative QFT test results were interpreted according to the
manufacturer’s algorithm using QFT software version 2.62.
PBMC Cryopreservation and in vitro
Mycobacterial Growth Inhibition Assay
Heparinized blood (> 10mL) collected in a cell preparation
tube (CPT; Novamed, Jerusalem, Israel) was centrifuged at 1,150
× g for 20min without deceleration. The peripheral blood
mononuclear cell (PBMC) layer was transferred to a fresh
tube and washed 2 times with Hanks’ balanced salt solution
(HBSS; Welgene, Gyeongasn, Republic of Korea). After adding
one milliliter of 1 × Pharm-Lyse solution (BD Biosciences,
New Jersey, USA), the PBMCs were incubated for 5min at
room temperature to disrupt erythrocytes. After washing, the
PBMCs were frozen in fetal bovine serum (FBS; Invitrogen,
Massachusetts, USA) with 10% dimethylsulfoxide (DMSO;
Sigma, Missouri, USA) and stored at −80◦C for 24 h before
transferring to liquid nitrogen until used. Cryopreserved PBMCs
were thawed and rested for 2 h at 37◦C in RPMI 1640 (Hyclone,
Logan, UT, USA) with 10% FBS and 10 units/mL of benzonase
(Novagen), then washed and re-suspended in RPMI 1640 with
25mM HEPES supplemented with 2mM L-glutamine and 10%
filtered, heat-inactivated, pooled human AB serum (Sigma). One
million of PBMC (1 × 106) were co-cultured in 2-mL screw-
cap tubes for 4 days with 100 colony forming units (CFU) of
BCG Pasteur at 37◦C with 360◦ rotation in a final volume of
600 µL. All samples were run in duplicate. Following incubation,
600 µL samples were transferred into a Mycobacterium Growth
Indicator tube (MGIT; BD, New Jersey, USA) supplemented with
PANTA enrichment, and the tube was placed in a BACTEC
MGIT 960 machine (BD, New Jersey, USA) and incubated
until mycobacterial growth rate was determined by the time to
positivity (TTP) as previously described (13, 22). As a control,
called “Direct-to-MGIT,” in which the bacterial inoculum being
used in the tubes is added directly to a MGIT tube, duplicate
MGIT tubes seeded with the sample concentration (100 CFU)
of BCG Pasteur without added cells were placed directly in the
BACTECMGIT 960 machine on day 0.
Diluted Whole Blood Intracellular Cytokine
Staining (ICS) Assays
As described by Smith et al. (29), venous blood (1mL) was
diluted 1:1 with warm Iscove’s modified Dulbecco’s medium
(IMDM; Invitrogen, Massachusetts, USA) in 15mL centrifuge
tubes (HYUDAI Micro, Seoul, Republic of Korea). Diluted blood
was incubated with medium only as a negative control or with
10µg/mL of Mtb purified protein derivate (PPD) for in vitro
use (Statens Serum Institute, Copenhagen, Denmark) or with
5µg/mL staphylococcus enterotoxin B (SEB; Sigma) as a positive
control. Co-stimulatory antibodies (2µg/mL each of anti-CD28
and anti-CD49d (BD Biosciences) were added to all tubes (33).
Assay tubes were incubated with loose lids for 2 h at 37◦C after
which 3µg/mL of brefeldin A (Sigma) was added to all tubes.
Following further 18 h incubation at 37◦C, 100 µL of 20mM
ethylenediamine-tetra acetic acid (EDTA, Sigma) was added and
incubated at room temperature for 15min. Diluted blood was
then incubated with 10 volumes of 1× FACS Lysing Solution (BD
Biosciences) at room temperature for 10min to lyse red blood
cells, centrifuged and washed with 3mL PBS, and pelleted cells
were stored in FBS with 10% DMSO at −80◦C for 24 h before
transferring to liquid nitrogen until assayed. After thawing and
washing with 3mL PBS, cells were surface stained with anti-
CD4-APC-H7 (BD Biosciences), anti-CD19-efluor450, and anti-
CD14-efluor450 (eBiosciences, California, USA) for 30min at
4◦C. After washing in PBS/0.1% BSA/0.01% sodium azide, cells
were permeabilized and fixed with Cytofix/Cytoperm reagent
(BD Biosciences) at 4◦C for 20min washed in Perm Wash
buffer (BD Biosciences) and stained with anti-CD3-Horizon-
V500, anti-IL-2-FITC, anti-TNFα-PE-Cy7 (BD Biosciences), and
anti-IFNγ-PerCP-Cy5.5 (Biolegend, California, USA) for 30min
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at room temperature. Cells were then resuspended in 250 µL
1% paraformaldehyde (Sigma) and analyzed within 24 h after
staining. Data was acquired using an LSR 4-laser Fortessa
flow cytometer (BD Biosciences) and FACSDiva acquisition
software (BD Biosciences). Analysis was performed using FlowJo
(TreeStar Inc., Oregon, USA).
Statistical Analysis
GraphPad Prism 6 software (La Jolla, CA, USA) was used to
perform statistical analyses as described in the figure legends.
Mean and SD were calculated for continuous measures, and
the Fisher’s exact test was used for dichotomous measures.
Statistical comparisons between study groups were made using
the Mann-Whitney U-test and Fisher’s exact test. Associations
between growth inhibition and ICS responses were measured
using Spearman’s rank correlation coefficient (r). All P-values
were two-sided, and P < 0.05 was considered to be statistically
significant. To determine the relationship between age and QFT
test results of study participants, we employed a Generalized
Additive Model (GAM) with logit link function with P-spline
smothers (Supplementary Figure 1) (34). For ICS assay, the data
was analyzed using FlowJo software version 9.1 (TreeStar Inc.,
Ashland, OR) and SPICE version 5.1 (freely available from http://
exon.niaid.nih.gov/spice/). Samples were gated sequentially
on singlet, CD14-CD19-, lymphoid, CD3+CD4+ cells and
negative control stimulation tubes were used to set cytokine
gates (Supplementary Figure 2).
RESULTS
Study Participants
We enrolled 121 Korean healthy adults aged more than 20 years
old having a normal chest X-ray and no history of tuberculosis.
The mean age of all the study participants was 35.1 (SD ±11.4)
years, 26.4% (n = 32) were male, and 69.4% had detectable BCG
scars. The mean ages of the QFT positive (42.3 years ±13.6)
and QFT negative groups (32.1 years ± 8.9) were statistically
different (P = 0.0001). However, the data shows that other
general characteristics of the participants including gender and
presence of a BCG scar did not affect the result of the QFT-GIT
test (Table 1).
In vitro Mycobacterial Growth Inhibition
Ability in Healthy South Korean Adults
As shown in Table 1, there was a statistical difference in mean
ages between the QFT positive and negative groups using this
IGRA assay which aids in diagnosingMtb infection (P= 0.0001).
This indicates that age may affect the Mtb infection status as
found in Korean National TB data (3, 6).
For subsequent analysis of MGIA results, the data was
categorized at cut-off age of 40 years by the risk for Mtb
infection based on the relationship between QFT results and age
in study participants (Supplementary Figure 1). For the results
of the PBMC-based MGIA response analyzed by demographic
characteristics of study participants, no significant difference in
TTP by age group, gender or BCG status was observed as shown
in Figures 1A–C.
For MGIA assays, mycobacterial growth in each tube
was determined by TTP in hours. MGIA assays were run
on 16 separate occasions to examine the repeatability and
intermediate precision, TTP hours from direct-to MGIA tubes
as controls were compared (mean 219.7 h ± 15.3). The intra-
assay (within-run precision or repeatability) and inter-assay
(between-run precision or inter precision) precision coefficients
of variation (% CV) were determined to be 2.92 and 6.44%,
respectively (Supplementary Figure 3).
MGIA Response Analyzed by the Status of
TB Infection in Healthy Korean Adults
MGIA responses expressed in TTP were compared between the
QFT positive and negative test groups using a dichotomous
cutoff at 0.35 IU/mL as recommended by the manufacturer.
The data shows that individuals with QFT negative results had
significantly longer TTP in hours showing that those with QFT
negative results had a better ability to inhibit the growth of
BCG (P = 0.0266, Figure 2A). Regarding the reliability of QFT
testing for the diagnosis of latent TB infection, several studies
have demonstrated that the results of serial QFTs were often
not consistent possibly due to immunological and technical
variability, and in longitudinal studies both QFT conversions and
reversions can be observed (35).
For better interpretation of QFT results, Nemes et al. recently
proposed three categories of QFT IFN-γ values: < 0.2 IU/mL as
true negatives, 0.2–0.7 IU/mL as an uncertainty zone, and > 0.7
IU/mL as true positives. Based on these three categories of QFT
IFN-γ values, MGIA responses (in TTP hours) were compared.
Individuals with IFN-γ values < 0.2 IU/mL had significantly
longer TTP than those with IFN-γ values> 0.7 IU/mL indicating
that the QFT true negatives (< 0.2 IU/mL) had better ability to
inhibit the growth of BCG (P = 0.0154, Figure 2B).
In addition, we grouped study participants into LTBI or
healthy control (HC) groups, based on clinical as well as
laboratory evaluation. Over half (52.9%, n = 64) of the study
participants had recent contact with a known TB patient within
the last year and were defined as a “known TB contact.” The
rest of the participants (n = 57) who had no recent contact
with known TB patients were defined as “no known TB contact.”
In addition to clinical evaluation in terms of exposure to Mtb
we tested all study participants with the QFT assay. Of the
known TB contacts, 32.8% (n = 21) were QFT positive and
were defined as individuals with LTBI. Of those without any
known TB contact, 75.4% (n = 43) were QFT negative, and
were defined as healthy controls in this study (Figure 3). The
MGIA response was compared between the LTBI andHC groups.
The data shows that there was significantly greater reduction in
growth of mycobacteria in HCs without known TB contact who
had longer TTP than in those with LTBI and known TB contact
(P = 0.0005, Figure 2C).
From observation of these MGIA responses in healthy adults,
it appears that the status of TB infection in S. Korea, an area
with an intermediate burden of tuberculosis, seems to affect the
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TABLE 1 | General characteristics of study participants by QFT-GIT assay.
QFT-GIT assay* n (%) Age Gender Presence of a BCG scar(s)
Mean years ± S.D. Male, n (%) Yes, n (%)
Positive (IFN-γ ≥ 0.35 IU/ml) 35 (28.9) 42.3 ± 13.6 12 (34.2) 21 (60.0)
Negative (IFN-γ < 0.35 IU/ml) 86 (71.1) 32.1 ± 8.9 20 (23.2) 63 (73.2)
P-value 0.0001a 0.2571b 0.1921b
All 121 (100) 35.1 ± 11.4 32 (26.4) 84 (69.4)
*QFT-GIT assay: The QuantiFERON-TB Gold In-Tube, with the results defined as per manufacturer’s guideline.
aMann-Whitney test; bFisher’s exact test.
FIGURE 1 | MGIA results in comparison with general characteristics of participants. Cryopreserved PBMC prepared from blood samples from 121 healthy adults were
thawed and incubated with BCG for 4 days after which remaining mycobacteria were quantified using BACTEC MGIT tubes. In vitro mycobacterial growth in the
PBMC based-MGIA assay is presented in panel (A) by age group, in (B) by gender, and in (C) by presence of a BCG scar(s) in healthy adults. A Mann-Whitney U-test
was used for comparison of the two groups. P-value ≤ 0.05 was taken as statistically significant. The growth of BCG Pasteur was plotted as TTP (Time to Positive) in
hours.
FIGURE 2 | Comparison of MGIA response as TTP (Time to Positive) in hours stratified by QuantiFERON-TB Gold In-Tube (QFT) IFN-γ values in LTBI or HC
individuals. MGIA responses of healthy adults (n = 121) were stratified by QFT IFN-γ values at baseline. (A) Comparison of MGIA response as TTP in hours between
the QFT+ (positive test results) and QFT- (negative test results) groups, according to the manufacturer’s assay using < 0.35 IU/mL and > 0.35 IU/mL IFN-γ values; (B)
MGIA response as TTP in hours, stratified by the three categories of IFN-γ values: > 0.7 IU/mL, between 0.2 and 0.7 IU/mL, and < 0.2 IU/mL; (C) Comparison of
MGIA response as TTP in hours between individuals with latent TB infection (LTBI) defined as QFT + with known contact history with TB patients and healthy controls
(HC) defined as QFT—without recent contact history with known TB patients. P-values were calculated using Mann-Whitney U-test.
results of PBMC-based in vitro MGIA, demonstrating a greater
ability to inhibit the growth of BCG in healthy controls than those
with LTBI.
Relationship Between MGIA and ICS
Assays and the Status of TB Infection
In this study, based on a diluted whole blood ICS assay,
we also measured the frequency of PPD-specific CD4+
T-cells producing IFN-γ, TNF-α, and IL-2 in nineteen
study participants. Median cytokine responses in negative
control tubes, as a percentage of the gated CD4+ T-cell
population, were as follows: IFN-γ: 0.044%; TNF-α: 0.075%;
IL-2: 0.028%. Median cytokine responses in positive control
tubes (SEB-stimulated) were as follows: IFN-γ: 1.810%; TNF-α:
3.790%; IL-2: 4.050% (Supplementary Figure 4). The CD4+
T-cell populations producing IFN-γ and IL-2 were more
dominant in the LTBI group than the HC group, respectively
(P = 0.0050, P = 0.0011, Figure 4A). Also, the frequency of
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FIGURE 3 | Flow chart of study participants enrolled. A total of 121 Korean healthy adults aged more than 20 years old with normal chest x-ray results and without
any tuberculosis history agreed to participate in the study at the Severance Hospital, Seoul. Sixty-four participants had had known contacts with TB patients within the
past year. The other participants had had no known previous contacts with TB patients. In addition to clinical evaluation in terms of exposure to M. tuberculosis, we
tested all study participants with QFT-GIT test for diagnosis of TB infection. Of the known TB contacts, 32.8% (n = 21) were QFT positive and defined as individuals
with LTBI. In those without known TB contact, 75.4% (n = 43) were QFT negative, and were defined as healthy controls (HC) in this study.
PPD-specific IFN-γ+IL-2+ TNF-α+ polyfunctional CD4+T-
cells were dominant in the LTBI group (P = 0.0002, Figure 4B).
These data supported that infection with Mtb activates an
antigen-specific, polyfunctional Th-1 response in this study
population. However, scatter plots of MGIT TTP in hours
vs. the frequency of polyfunctional CD4+ T-cells shows
growth inhibition ability did not correlate with PPD-specific
polyfunctional CD4+ T cells in the samples (n = 19) where
both MGIA and ICS assays were performed (Figure 4C). CD4+
T cells producing single cytokines also did not correlate with
TTP (Supplementary Figure 5). When the association between
the frequency of polyfunctional CD4+ T-cells and MGIT TTP
was analyzed separately by the category of QFT values (true
negatives, uncertainty zone, and true positives), there also was
no correlation between ICS andMGIA assay (results not shown).
Higher PPD-specific, polyfunctional Th-1 responses in whole
blood did not predict any enhancement of MGI ability in PBMC.
DISCUSSION
According to a Korean national annual report in 2016, the TB
incidence rate increased in young Koreans in the 15–19 age
group and showed a peak response in those over 65 years in S.
Korea. The proportion of TB cases among immigrants has been
increasing from 2.5% in 2011 to 6.9% in 2016 (6). These national
statistics indicate that there must be ongoing transmission in
group settings such as schools, military settings and workplaces,
and also there must be reactivation of TB in the elderly. Besides
childhood BCG vaccination, innovative efforts for new adult
TB vaccination need to be evaluated to control adult TB in S.
Korea. Prior to human trials for novel TB vaccine candidates,
it is essential to understand the baseline immune responses of
potential vaccine target populations in particular.
Based on the MGIA response in healthy adult controls,
demographical characteristics of the healthy adults including age
group, gender, and the status of historical BCG scar did not
affect the result of mycobacterial growth inhibition in PBMC
(Figure 1). However, the QFT negative group (QFT IFN-γ <
0.35 IU/mL) revealed longer TTP, showing that those individuals
had a better ability to inhibit mycobacterial growth compared
to the QFT positive group (P = 0.0266) in this assay using
PBMC. This result was reaffirmed by subdividing those tested
into three categories of QFT IFN-γ values (< 0.2 IU/mL, between
0.2 and 0.7 IU/mL, and > 0.7 IU/mL); the greater the IFN-γ
response to TB specific antigens was, the less was their ability
to inhibit mycobacterial growth (P = 0.0154). Moreover, the
difference in MGIA response was greatest when healthy adults
were categorized into LTBI and HC groups more stringently,
based on clinical (contact history) and laboratory assessment
(QFT testing). TheHC groupwithout knownTB contact revealed
significantly longer time to culture positive hours indicating
this group had better ability to inhibit mycobacterial growth
compared with the LTBI group who had known recent TB
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FIGURE 4 | ICS data in LTBI and healthy control groups and correlation between mycobacterial growth inhibition and ICS responses. (A) Single cytokine expression
data including IFN-γ, IL-2, and/ or TNF-α for individuals with LTBI (black bars, n = 11) and healthy controls (gray bars, n = 8). The PPD-specific CD4+ T-cell
populations making IFN-γ and IL-2 are dominant in the LTBI group. (B) The polyfunctionality of CD4+ T-cell populations in individuals with LTBI (black bars) and HCs
(gray bars). The PPD-specific polyfunctional T helper-1 cells are the dominant cell type in the LTBI group. Whole blood samples obtained from healthy adults were
stimulated with PPD overnight and CD4+ T-cells assessed for cytokine secretion by intracellular staining. All ICS data is plotted as bars showing medians and
interquartile ranges. Whiskers show the range of the data. The Mann-Whitney U-test was used to determine significance. (C) Scatter plots of TTP in hours vs. the
percentage of polyfunctional CD4+ T-cells were drawn for all samples where both the mycobacterial growth inhibition assay (MGIA) and the ICS assay were
performed (n = 19). Inhibition of mycobacterial growth (of BCG Pasteur) is indicated by TTP in hours for the remaining mycobacteria after incubation with PBMC
obtained from study participants. The Mann-Whitney U-test was used to compare growth inhibition ability between the LTBI and HC groups. Spearman’s rank
correlation coefficient was calculated between growth inhibition and ICS data, indicated as r.
contact (P = 0.0005). These results seemed to be contradictory
to other recent data (17) where the LTBI group as a whole
showed no difference from healthy controls unless exposure
was more recent, in which case, growth inhibition was better
than the healthy control group. O’Shea et al. also noted that
samples from those with active TB disease had better growth
inhibition of mycobacteria than LTBI, and that those with
LTBI had better growth inhibition of mycobacteria than healthy
controls, suggesting that the immune response becomes more
effective during active disease or recent infection (24). One
reason that might explain this difference in MGIA response
in these different studies might be differences between the
characteristics of the groups recruited in the different studies.
Our study defined “healthy controls” as all Korea-born adults
with no known contacts with an active TB patient, negative QFT
result, and with a history of BCG vaccination. On the other hand,
healthy controls in the study by Joosten et al. were BCG naïve,
recruited in the Netherlands and Norway where the burden of
TB is low and childhood BCG vaccination is not a part of the
national immunization program. Healthy controls living in a
country with an intermediate burden of TB and with different
environmental exposure to non-tuberculous mycobacteria may
have a different ability to control mycobacterial growth in
the body than those living in European settings. Another
reason to explain this difference in MGIA response might be
the different cellular and non-cellular components in whole
blood containing neutrophils, antibodies, and complement,
which would not be present in the assays using PBMC (36–
39). Our study performed in vitro experiments with frozen
PBMC while the results from the O’Shea group used a whole
blood MGIA, and hematological characteristics of the different
cell types could affect the results of the assay (25). There
may also be differences in the proportions of classical: non-
classical monocytes in different populations and settings, which
may impact on growth inhibition as CD14 low non-classical
monocytes have been shown to be associated with growth
inhibition (17).
This study demonstrated that infection with Mtb activates an
antigen-specific, polyfunctional Th-1 response as the magnitude
of PPD-specific IFN-γ+ IL-2+ TNF-α+ polyfunctional CD4+T-
cells was greatest in the LTBI group (P = 0.0002) in
comparison with the HC group. However, the PPD-specific,
polyfunctional Th-1 response in whole blood was not associated
with mycobacterial growth inhibition ability in PBMC. These
results support previous findings that a positive antigen-specific
T-cell immune response does not correlate with the functional
immune response measured in the MGIA (17, 40). The only
study where the frequency of antigen-specific polyfunctional
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CD4 T-cells was correlated with in vitro mycobacterial growth
inhibition was performed in BCG-vaccinated infants in the UK
(29), this may reflect differences between adults and the infant
cohort that was used in that study.
As a result of collaboration efforts in the TBVAC2020
consortium, we now have standardized and improved protocols
available for MGIA as a novel assay and ICS as a reference
assay that can be used in TB vaccine trials in S. Korea.
As shown in previous studies (14, 15, 29), we found that
the current MGIA assay was reproducible and reliable with
2.92% of the intra-assay and 6.44% of the inter-assay in
this study (Supplementary Figure 3), within the limits set
for such biological assays that would be used in clinical
trials. A MGIT assay using frozen PBMC as performed here
is more suitable for use in a vaccine trial than a whole
blood assay, as frozen PBMC collected before and at different
time points post-vaccination can be directly compared in the
same assay.
We performed a cross-sectional study to measure baseline
immune response in terms of WB-based ICS and PBMC-based
MGIA from Korean healthy adults. To our knowledge, the
current study demonstrated the first observation of the PBMC-
based MGIA in healthy adults exclusively recruited from S.
Korea, a country with an intermediate burden of tuberculosis.
Given the population/geographical differences in BCG vaccine
efficacy (9) and BCG-induced immune responses (41, 42)
previously seen, it will be important to evaluate novel and
existing biomarker assays in diverse cohorts in order to take
these immunological differences into account. This study aimed
to assess how the MGIA assay performed in South Korea. The
assay has now been used in studies performed in the UK and the
Netherlands (17, 24) but more work is needed to compare the
performance of theMGIA assay using the now standardized SOP,
in other settings and ethnic groups. For further investigations,
we also plan to perform the Mtb-based MGIA assay in TB
patients, who will be the target population for therapeutic
TB vaccination. The use of Mtb rather than BCG might be
important to monitor treatment efficacy after drug therapy in
parallel with therapeutic vaccination, and we plan to use Mtb in
these studies.
In conclusion,Mtb infection status had a significant impact on
the mycobacterial growth inhibition ability tested using PBMC
from individuals in S. Korea. More work is required to define
the key components of the mycobacterial growth inhibition
observed. However, the assay proved robust and reproducible
and can be used to assess the induction of mycobacterial growth
inhibition in clinical trials of new TB vaccines.
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